SRX3177
SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of E protein and the BRD2/4 BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer[1][2].
Product Specifications
CAS Number
[2241237-51-2]
UNSPSC
12352005
Target
CDK; Epigenetic Reader Domain; NF-κB; PI3K; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Epigenetics; NF-κB; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection; Inflammation/Immunology; Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/srx3177.html
Purity
99.59
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C1C=C(N2CCOCC2)OC3=C1SC=C3C4=CC=C(NC5=NC6=C(C=C(N6C7CCCC7)C(N(C)C)=O)C=N5)C=C4
Molecular Formula
C31H32N6O4S
Molecular Weight
584.69
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-153894/SRX3177-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-153894/SRX3177-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4; CDK4; CDK6; PI3Kα; PI3Kβ; PI3Kγ
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
